Citations refer to the original publication, not to a Scieee localized version.
Martínez, C., Corral Carpio, C., Heras, I., Ríos Herranz, E., Buch, J., Gutierrez, A., & García-Sanz, R. (2022). Potential Survival Benefit for Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation after Nivolumab Therapy for Relapse/Refractory Hodgkin Lymphoma: Real-Life Experience in Spain. Elsevier Science Inc. https://doi.org/10.1016/j.bbmt.2020.02.003
Martínez, Carmen, et al. Potential Survival Benefit for Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation after Nivolumab Therapy for Relapse/Refractory Hodgkin Lymphoma: Real-Life Experience in Spain. Elsevier Science Inc, 2022. https://doi.org/10.1016/j.bbmt.2020.02.003.
Martínez, Carmen, Cecilia Corral Carpio, Inmaculada Heras, Eduardo Ríos Herranz, Joan Buch, Antonio Gutierrez, and Ramón García-Sanz. Potential Survival Benefit for Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation after Nivolumab Therapy for Relapse/Refractory Hodgkin Lymphoma: Real-Life Experience in Spain. Elsevier Science Inc, 2022. https://doi.org/10.1016/j.bbmt.2020.02.003.
Martínez, C. et al. (2022) Potential Survival Benefit for Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation after Nivolumab Therapy for Relapse/Refractory Hodgkin Lymphoma: Real-Life Experience in Spain. Elsevier Science Inc. Available at: https://doi.org/10.1016/j.bbmt.2020.02.003.
C. Martínez et al., “Potential Survival Benefit for Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation after Nivolumab Therapy for Relapse/Refractory Hodgkin Lymphoma: Real-Life Experience in Spain,” Elsevier Science Inc, 2022, doi: 10.1016/j.bbmt.2020.02.003.
@misc{martinez2022potential,
author = {Martínez, Carmen and Corral Carpio, Cecilia and Heras, Inmaculada and Ríos Herranz, Eduardo and Buch, Joan and Gutierrez, Antonio and García-Sanz, Ramón},
title = {Potential Survival Benefit for Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation after Nivolumab Therapy for Relapse/Refractory Hodgkin Lymphoma: Real-Life Experience in Spain},
year = {2022},
publisher = {Elsevier Science Inc},
doi = {10.1016/j.bbmt.2020.02.003},
url = {https://doi.org/10.1016/j.bbmt.2020.02.003}
}
The source metadata has no journal, volume or pages. Add them from the original publication if your citation needs them.
